SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-19-008291
Filing Date
2019-05-10
Accepted
2019-05-10 16:56:26
Documents
41
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0319_actiniumpharma.htm 10-Q 489443
2 CERTIFICATION f10q0319ex31-1_actinium.htm EX-31.1 9935
3 CERTIFICATION f10q0319ex31-2_actinium.htm EX-31.2 9742
4 CERTIFICATION f10q0319ex32-1_actinium.htm EX-32.1 4828
5 CERTIFICATION f10q0319ex32-2_actinium.htm EX-32.2 4837
  Complete submission text file 0001213900-19-008291.txt   2208142

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE atnm-20190331.xml EX-101.INS 229973
7 XBRL SCHEMA FILE atnm-20190331.xsd EX-101.SCH 36530
8 XBRL CALCULATION FILE atnm-20190331_cal.xml EX-101.CAL 31381
9 XBRL DEFINITION FILE atnm-20190331_def.xml EX-101.DEF 121892
10 XBRL LABEL FILE atnm-20190331_lab.xml EX-101.LAB 270696
11 XBRL PRESENTATION FILE atnm-20190331_pre.xml EX-101.PRE 189923
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 19815764
SIC: 2834 Pharmaceutical Preparations